Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Laser plus sclerotherapy vs sclerotherapy Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 2 studies · 710 participants | Low |
Laser plus sclerotherapy vs sclerotherapy Adverse events ‐ Hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.83 [0.35, 1.99] | 2 studies · 656 participants | Low |
Laser plus sclerotherapy vs sclerotherapy Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.83 [0.21, 3.28] | 2 studies · 656 participants | Low |
Laser plus sclerotherapy vs sclerotherapy Pain ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 2.44 [1.69, 3.55] | 1 study · 596 participants | Low |
Laser plus sclerotherapy vs sclerotherapy Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Laser plus sclerotherapy vs sclerotherapy Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Laser plus sclerotherapy vs sclerotherapy Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 2 studies · 191 participants | Moderate |
Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.79 [0.62, 1.01] | 2 studies · 191 participants | Moderate |
Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.78 [0.51, 1.2] | 2 studies · 191 participants | Moderate |
Sclerotherapy vs placebo Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) Pain ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 1.02 [0.83, 1.24] | 2 studies · 191 participants | Moderate |
Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy plus compression vs sclerotherapy alone Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 2 studies · 196 participants | Moderate |
Sclerotherapy plus compression vs sclerotherapy alone Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.93 [0.41, 2.07] | 2 studies · 196 participants | Moderate |
Sclerotherapy plus compression vs sclerotherapy alone Adverse events ‐ matting ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 1.84 [0.17, 19.62] | 1 study · 96 participants | Low |
Sclerotherapy plus compression vs sclerotherapy alone Pain · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy plus compression vs sclerotherapy alone Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy plus compression vs sclerotherapy alone Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy vs placebo Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy plus compression vs sclerotherapy alone Quality of life ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 1 study · 93 participants | Low |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | 7 studies · 852 participants | Moderate |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | RR 0.94 [0.62, 1.43] | 6 studies · 819 participants | Moderate |
[Axillary] B‐mode ultrasound guidance vs palpation and landmarks First‐attempt success rate · adults requiring axillary artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Dorsalis pedis] B‐mode ultrasound guidance vs palpation and landmarks Overall success rate · adults requiring dorsalis pedis artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 1 [0.91, 1.1] | 1 study · 60 participants | Very low |
[Dorsalis pedis] B‐mode ultrasound guidance vs palpation and landmarks Time needed for a successful procedure · adults requiring dorsalis pedis artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | 1 study · 60 participants | Very low |
[Dorsalis pedis] B‐mode ultrasound guidance vs palpation and landmarks Major haematoma · adults requiring dorsalis pedis artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Dorsalis pedis] B‐mode ultrasound guidance vs palpation and landmarks Adverse events (pain) · adults requiring dorsalis pedis artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Dorsalis pedis] B‐mode ultrasound guidance vs palpation and landmarks Quality of life · adults requiring dorsalis pedis artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] B‐mode ultrasound guidance vs palpation and landmarks First‐attempt success rate · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 1.44 [1.29, 1.61] | 27 studies · 4708 participants | Low |
[Radial] B‐mode ultrasound guidance vs palpation and landmarks Pseudomaneurysm · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 2.89 [0.12, 70.63] | 1 study · 679 participants | Very low |
[Radial] B‐mode ultrasound guidance vs palpation and landmarks Overall success rate · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 1.11 [1.06, 1.16] | 28 studies · 4955 participants | Low |
[Radial] B‐mode ultrasound guidance vs palpation and landmarks Time needed for a successful procedure · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | 26 studies · 4902 participants | Low |
[Radial] B‐mode ultrasound guidance vs palpation and landmarks Major haematoma · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 0.35 [0.23, 0.56] | 16 studies · 2504 participants | Moderate |
[Axillary] B‐mode ultrasound guidance vs palpation and landmarks Pseudoaneurysm · adults requiring axillary artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] B‐mode ultrasound guidance vs palpation and landmarks Adverse events (pain) · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | 4 studies · 883 participants | Very low |
[Radial] B‐mode ultrasound guidance vs palpation and landmarks Quality of life (satisfaction) · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | 1 study · 72 participants | Very low |
[Radial] B‐mode ultrasound vs Doppler assistance First‐attempt success rate · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 1.35 [1.11, 1.64] | 1 study · 493 participants | Moderate |
[Radial] B‐mode ultrasound vs Doppler assistance Pseudoaneurysm · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] B‐mode ultrasound vs Doppler assistance Overall success rate · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 1.13 [0.99, 1.29] | 1 study · 493 participants | Low |
[Radial] B‐mode ultrasound vs Doppler assistance Time needed for a successful procedure · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | 1 study · 493 participants | Moderate |
[Radial] B‐mode ultrasound vs Doppler assistance Major haematoma · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] B‐mode ultrasound vs Doppler assistance Adverse events (pain) · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] B‐mode ultrasound vs Doppler assistance Quality of life · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] B‐mode ultrasound vs near‐infrared laser guidance First‐attempt success rate · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 1.33 [0.82, 2.16] | 1 study · 72 participants | Very low |
[Axillary] B‐mode ultrasound guidance vs palpation and landmarks Overall success rate · adults requiring axillary artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 1.35 [0.99, 1.86] | 1 study · 33 participants | Very low |
[Radial] B‐mode ultrasound vs near‐infrared laser guidance Pseudoaneurysm · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
[Radial] B‐mode ultrasound vs near‐infrared laser guidance Overall success rate · adults requiring radial artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | RR 1.5 [0.27, 8.45] | 1 study · 72 participants | Very low |